Free Trial
OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Price, News & Analysis

Vyant Bio logo
$0.19 +0.01 (+7.78%)
As of 12/29/2023

About Vyant Bio Stock (OTCMKTS:VYNT)

Key Stats

Today's Range
$0.18
▼
$0.20
50-Day Range
$0.19
▼
$0.19
52-Week Range
$0.14
▼
$1.58
Volume
19,100 shs
Average Volume
161,822 shs
Market Capitalization
$1.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vyant Bio, Inc. is a biotechnology company focused on improving drug discovery and development through human-relevant biological models and data-driven research. The company developed platforms designed to help pharmaceutical and biotechnology organizations evaluate potential therapies and better understand disease biology before clinical testing.

Its activities have included the development and use of patient-derived cells, organoids, stem-cell-based models and other advanced preclinical systems. These technologies were intended to support research in areas such as oncology, neurological disorders and other complex diseases, with services spanning assay development, drug screening, toxicology and preclinical testing.

Vyant Bio was formerly known as Cancer Genetics, Inc. and adopted its current name as it expanded beyond cancer-focused genomic testing and research services. The company operated through a combination of internal platforms and acquired businesses serving pharmaceutical and biotechnology customers. Publicly available information about its current operations, leadership and geographic reach is limited.

AI Generated. May Contain Errors.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VYNT Stock News Headlines

Vyant Bio Inc VYNT
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
Vyant Bio, Inc.: Vyant Bio Provides Update on Winddown Activities
Vyant Bio Provides Update on Winddown Activities
See More Headlines

VYNT Stock Analysis - Frequently Asked Questions

Vyant Bio's stock was trading at $0.1940 at the beginning of 2026. Since then, VYNT stock has increased by 0.0% and is now trading at $0.1940.

Vyant Bio, Inc. (OTCMKTS:VYNT) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to analysts' expectations of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%.
Read the conference call transcript
.

Vyant Bio shares reverse split on Wednesday, November 2nd 2022.The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/11/2021
Today
10/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:VYNT
CIK
1349929
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.69 million
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%
Return on Equity
-151.82%
Return on Assets
-97.14%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
2.86
Quick Ratio
2.86

Sales & Book Value

Annual Sales
$670 thousand
Price / Sales
1.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.69 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
6,330,000
Free Float
5,724,000
Market Cap
$1.23 million
Optionable
Not Optionable
Beta
1.73
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:VYNT) was last updated on 10/5/2026 by MarketBeat.com Staff.
From Our Partners